AstraZeneca

Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale. In the podcast, Mohit Manrao, the SVP and head of US oncology at AstraZeneca, shares his…

Speaking at the Citywire Elite Companies Awards, AstraZeneca (GB:AZN) director of investor relations Phil Sparks discusses how the pharmaceutical giant is using artificial intelligence (AI) across its business. He says the company is working with partners to use AI to ‘ingest huge amounts of scientific data... which could help us identify new targets for future…

AstraZeneca’s pioneering artificial intelligence (AI) research centre could fall into foreign ownership under reported plans for the drugs giant to spin off and separately list its Chinese division. The British company is said to be considering a plan that would see it hive off its China business and float it on a stock market in…

Today, Breast Cancer Canada, a national charity dedicated to saving lives through breast cancer research, announced a new research grant in collaborat

Data science to improve clinical practice and clinical trials Advances in data science and data utilisation are key to improving clinical trials and real-world evidence through which medicines are regulated and optimised. The quest for inclusive trials seeks fair representation of patient groups across all lived-experiences – including people from low- and middle-income countries or…

Research, presented by AstraZeneca, provides information on the biological validation of Serum Response Factor as a potential target for idiopathic pulmonary fibrosis The target was discovered using the Benevolent Platform™, BenevolentAI’s AI-enabled drug discovery engine, leveraged in a target identification collaboration between AstraZeneca and BenevolentAI A total of five AI-generated targets have been selected for portfolio-entry in…

Research, presented by AstraZeneca, provides information on the biological validation of Serum Response Factor as a potential target for idiopathic pulmonary fibrosis The target was discovered using the Benevolent Platform™, BenevolentAI’s AI-enabled drug discovery engine, leveraged in a target identification collaboration between AstraZeneca and BenevolentAI A total of five AI-generated targets have been…

Cordio Medical’s HearO app analyzes the voice of heart failure patients to monitor their condition. [Photo courtesy of Cordio Medical] AstraZeneca and the Bellvitge University Hospital plan to launch the first pilot program for the Cordio Medical HearO app. The HearO smartphone app provides widespread access to medical-grade technology for patients with congestive heart failure (CHF).…

AstraZeneca is pushing forward with implementing artificial intelligence (AI) in early cancer diagnosis and drug treatment plans with the hope of significantly reducing mortality rates over the next two decades. David Fredrickson, the Executive Vice-President of the company's Oncology Business Unit, recently expressed his hope for the future of oncological work at the Milken Institute…

Artificial intelligence (AI) is evolving into a powerful tool for helping scientists develop new, innovative treatments for cancer.1 While progress is being made, to fully realise the potential of AI we need to maximise the use of our clinical and multi-omics data. To enable this, our Data Science teams are optimising our data and AI…

AstraZeneca (AZ) is partnering with artificial intelligence (AI) tech company Qure.ai and the Greater Manchester Cancer Alliance to evaluate whether an AI system can help radiologists make faster and more accurate diagnoses of lung cancer. Qure.ai’s qXR technology will be used to review X-rays of around 250,000 people in Greater Manchester, where the companies say…

AstraZeneca's Leif Johansson says AI and screening could prevent costly treatment in hospitals.